The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Why "dose equivalence" between different incretin analogues is a weak concept

This is a generated summary. It shows the 9 most-liked posts from a topic of 134, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
PN
p.novotnyTL2Regular14 Feb 2026#8

Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.

27 likes 5mo
VS
vial_slopeTL3Regular Solution15 Feb 2026#10

There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".

The conclusion is tentative; the arithmetic underneath it is not.

7 likes 5mo
SK
s.karlsen_rphTL3Pharmacist17 Feb 2026#52

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

32 likes 5mo
BD
baseline_driftTL2Analytical chemist18 Feb 2026#65

Post #61 put the caveat in the right place and I want to underline it.

The most common practical error is not the schedule at all — it is losing track of which step you are on after a break, and then resuming at the top rather than re-approaching it.

That is the version I use. It may not be the version that is correct.

27 likes 5mo
RI
r.ilungaTL219 Feb 2026#84
vial_slope, post #10: There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine". The conclusion is tentative; the arithmetic underneath it is not. Go to post

Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.

Small point, but it is the one that usually catches people.

28 likes in reply to #10 5mo
GH
g.haalandTL3Regular19 Feb 2026#89
m.perrin, post #51: When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue. Go to post

Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.

27 likes in reply to #51 5mo
FP
forest_plotTL3Evidence synthesis20 Feb 2026#95
t.steenkamp, post #76: Post #75 put the caveat in the right place and I want to underline it. Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that very small increments are hard to measure accurately with a syringe. Old habit: I write down the… Go to post

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.

28 likes in reply to #76 5mo
SS
s.solbergTL220 Feb 2026#106

Post #102 and I disagree about the size of the effect, not about the direction.

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

Second-hand, so weight it accordingly.

32 likes 5mo
SP
s.poulsenTL3Regular21 Feb 2026#127

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

Reading it back, the second half matters more than the first.

27 likes 5mo

Read the full topic (134 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. A question about steady state that I think has a definite answer,…
LWPADMHKM+31 35 2k 1d
About the Dosing & titration category
Schedules, escalation intervals, dose reductions, and the arithmetic that connects a vial to a syringe mark. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
JMKILDNAW 4 350 4mo
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. An honest uncertainty about titrating on tolerability rather than a disguised…
POCCMH 2 31k 13mo
The lowest dose that does anything: is that a real question?
Asking directly, because I could not find a straight answer: The lowest dose that does anything: is that a real question? I have read the maintained page on this and I still have a gap, so I am asking rather…
PPDFPGDVS+100 111 9.1k 5mo
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on…
ESKHVKASNP+99 110 61k 2d

Related topics — sharing the tags tirzepatide, dose reduction, titration

TopicParticipantsRepliesViewsActivity
Follow-up: Escalating every six weeks instead of four: what I observed over eight months
Escalating every six weeks instead of four: what I observed over eight months — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
VSHKLMEKN 4 164 20mo
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Something about Tirzepatide…
BNNSKFCBP+109 122 3.6k 2mo
About the Semaglutide category
GLP-1 receptor agonist. Dosing, published trial data, tolerability, and formulation questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with…
TVJMRJGOMH 4 4.2k 11mo
How much of the diluent volume the powder itself displaces
Asking directly, because I could not find a straight answer: How much of the diluent volume the powder itself displaces Writing this out with the numbers in it, because "roughly" is how these go wrong. Vial:…
CCFPHI 2 1.8k 1d
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
KTVSMNARF 4 32k 8mo